Bio Research and development A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark

 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  8.2% 7.8% 27.0% 3.4% 41.3%  
Credit score (0-100)  32 32 3 54 0  
Credit rating  BB BB B BBB C  
Credit limit (kDKK)  0.0 0.0 -0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12

Net sales  0 0 0 0 0  
Gross profit  85.0 198 -379 3,189 -795  
EBITDA  35.7 81.8 -516 2,280 -1,862  
EBIT  33.2 74.2 -525 2,246 -1,914  
Pre-tax profit (PTP)  32.5 58.1 -514.2 2,205.8 -1,946.4  
Net earnings  27.1 35.4 -510.8 1,825.7 -1,932.6  
Pre-tax profit without non-rec. items  32.5 58.1 -514 2,206 -1,946  

 
See the entire income statement

Balance sheet (kDKK) 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12

Tangible assets total  23.2 15.6 20.0 278 226  
Shareholders equity total  27.1 62.6 -448 1,378 -855  
Interest-bearing liabilities  184 139 243 188 102  
Balance sheet total (assets)  349 438 253 3,095 1,110  

Net Debt  150 139 229 138 102  
 
See the entire balance sheet

Volume 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  85.0 198 -379 3,189 -795  
Gross profit growth  0.0% 132.6% 0.0% 0.0% 0.0%  
Employees  1 1 1 2 2  
Employee growth %  0.0% 0.0% 0.0% 100.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  349 438 253 3,095 1,110  
Balance sheet change%  0.0% 25.5% -42.2% 1,121.9% -64.1%  
Added value  35.7 81.8 -516.2 2,254.6 -1,862.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  21 -15 -4 224 -104  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 1.0 -1.0  

Profitability 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  39.1% 37.5% 138.4% 70.4% 240.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  9.6% 19.0% -82.1% 118.7% -75.6%  
ROI %  16.0% 36.0% -222.7% 173.9% -156.0%  
ROE %  100.0% 79.0% -323.4% 223.9% -155.4%  

Solidity 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
Equity ratio %  7.8% 14.3% -63.9% 44.5% -43.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  418.6% 169.5% -44.4% 6.1% -5.5%  
Gearing %  677.3% 221.8% -54.2% 13.7% -11.9%  
Net interest  0 0 0 0 0  
Financing costs %  1.3% 10.4% 8.1% 22.0% 24.0%  

Liquidity 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
Quick Ratio  0.3 0.3 0.2 1.1 0.1  
Current Ratio  1.0 1.1 0.3 2.8 0.4  
Cash and cash equivalent  34.2 0.3 13.5 50.4 0.1  

Capital use efficiency 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -6.8 39.6 -479.1 1,725.1 -1,242.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
Net sales / employee  0 0 0 0 0  
Added value / employee  36 82 -516 1,127 -931  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  36 82 -516 1,140 -931  
EBIT / employee  33 74 -525 1,123 -957  
Net earnings / employee  27 35 -511 913 -966